D. E. Shaw & Co., Inc. Aurinia Pharmaceuticals Inc. Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Aurinia Pharmaceuticals Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 133,333 shares of AUPH stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
133,333
Previous 93,949
41.92%
Holding current value
$1.04 Million
Previous $688,000
73.98%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding AUPH
# of Institutions
229Shares Held
56.9MCall Options Held
858KPut Options Held
1.57M-
Black Rock Inc. New York, NY9.27MShares$72.2 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA8.43MShares$65.7 Million5.69% of portfolio
-
Armistice Capital, LLC New York, NY6.4MShares$49.9 Million0.81% of portfolio
-
Nea Management Company, LLC Timonium, MD3.97MShares$30.9 Million2.55% of portfolio
-
State Street Corp Boston, MA2.92MShares$22.7 Million0.0% of portfolio
About Aurinia Pharmaceuticals Inc.
- Ticker AUPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,892,000
- Market Cap $1.11B
- Description
- Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...